Immune responses and immunoregulation in relation to human schistosomiasis in Egypt. III. Immunity and longitudinal studies of in vitro responsiveness after treatment.
Immune responsiveness of schistosomiasis patients was assayed longitudinally, before and for two years after chemotherapeutic treatment with praziquantel, by in vitro peripheral blood mononuclear cell (PBMN) proliferation upon exposure to phytohaemagglutinin (PHA), or soluble schistosomal antigenic preparations from eggs (SEA), adult worms (SWAP) or cercariae (CAP). Parallel faecal and urine examinations documented the infection status of the patients during this time. Treatment resulted in substantially increased responsiveness to the schistosome-derived materials but not to PHA or C. albicans extract. The responses to SEA, SWAP, and CAP often remained elevated for one to two years after treatment. However, those patients who became reinfected had significantly lower PBMN responses to SEA or CAP at the time of the last blastogenesis assay before the observation that they were again stool-positive for Schistosoma mansoni eggs. No other demonstrable differences (such as age, sex, household location, pre-treatment intensities of infection or occupation) were observed between those who remained uninfected for at least two years (resistant?) and those who became reinfected during this time (susceptible?).
D000293:Adolescent; D000328:Adult; D000947:Antigens, Helminth / Q000276:immunology; D002648:Child; D005260:Female; D006801:Humans; D007109:Immunity; D008137:Longitudinal Studies; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D011223:Praziquantel / Q000627:therapeutic use*; D012553:Schistosomiasis haematobia / Q000188:drug therapy / Q000276:immunology*; D012555:Schistosomiasis mansoni / Q000188:drug therapy / Q000276:immunology*
D000947:Antigens, Helminth; D011223:Praziquantel